HKEX-listed biotechs. Pipeline valuation anchored to observable licensing transactions, not DCF assumptions.
Take any HKEX biotech that listed since 2018 under Chapter 18A. There is a good chance it now has an approved drug, real revenue, and a licensing deal with a global pharma company sitting on the balance sheet. The market still trades the whole company as if everything depended on one upcoming trial.
That gap is the trade. A licensing deal is not an opinion. It is a price set by a serious buyer after months of diligence. Once you have that number, the rest of the company is not being priced anymore: it is residual. Subtract the deal's value from the market cap and what is left is what the public market pays for everything else: the approved drug, the rest of the pipeline, the platform. That number is usually a fraction of what comparable assets have transacted at. The work is not predicting the trial. The work is finding the companies where a serious buyer has already paid for the trial risk.
The headline number on a licensing deal is not the cash number. These deals are announced as a modest upfront payment against a much larger milestone total. The upfront has been paid. The milestones are contingent on trial readouts, regulatory filings and sales thresholds that most programmes never reach. I anchor on the upfront. Using the total is how a residual calculation quietly becomes a story.
The second check is the cash runway, and it comes before the science. A company with two years of cash and a partner who has already paid can wait for its readout. A company with four quarters of cash will raise money before the readout, at whatever price the market offers that week. The pipeline can be excellent and the existing shareholder still ends up diluted through the event that was supposed to pay them.
What disqualifies a name here: no partner, or a partner whose payment is small enough that it prices nothing. A deal a global pharma company negotiated over months of diligence is a valuation. A memorandum of understanding is a press release.
Most Chapter 18A listings fail the runway test, the partner test, or both. A page that listed them anyway would be a directory instead of a screen.
AstraZeneca Paid US$100M for One Molecule. The Rest Trades at US$507M.
AstraZeneca quantified the value of one Phase I asset at US$100M upfront, US$1.9B in milestones. Subtract net cash from the US$730M market cap and the rest of the company sits at US$507M. Approved drug, Phase III pipeline, platform: all of it.
← All analyses